Bluejay Diagnostics, Inc. - 8-K Filing
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II study showing an 18% mortality rate in sepsis and septic shock patients. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $BJDX